| Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
II. MODIFIED AGREEMENTS | |||
Altair Nano |
Spectrum Pharmaceuticals Inc. (SPPI) |
They resolved arbitration proceedings involving RenaZorb, and will continue to advance the product |
Altair will get 100,000 Spectrum shares for a milestone payment and 40,000 shares for product development improvements; the product targets kidney disorders (6/7) |
Asinex Ltd.* |
Ingenium Pharmaceuticals AG* (Germany) |
They agreed to continue their collaboration through 2006 |
The move followed successful lead optimization work done by Asinex; terms were not disclosed (6/6) |
Gen-Probe |
DiagnoCure Inc. (Canada; TSE:CUR) |
The amended and expanded deal focused on the PCA3 prostate cancer marker; also, DiagnoCure will fund research at Gen-Probe |
DiagnoCure got exclusive rights to develop in vivo products using the gene, and co-exclusive rights to develop fluorescence in situ hybridization products; Gen-Probe would get royalties on any resulting sales (5/30) |
XTL Bio- |
Cubist Pharmaceuticals Inc. (CBST) |
Cubist decided to discontinue its funding of HepeX-B, a drug candidate for preventing re-infection with hepatitis B following liver transplantation |
Cubist said the required pathway did not make financial sense; Cubist wants to find another partner or negotiate for XTL to regain rights (7/19) |
II. TERMINATED AGREEMENTS | |||
EndoBiologics |
VaxGen Inc. (PK:VXGN) |
VaxGen ended a deal for the development of a meningitis B vaccine candidate |
VaxGen had funded research and proof-of- concept studies under the May 2005 option agreement (5/30) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
PK = Pink Sheets; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.